Belgium
· Delayed Price · Currency is EUR BioSenic Statistics
Total Valuation
BioSenic has a market cap or net worth of EUR 1.23 million. The enterprise value is 27.27 million.
| Market Cap | 1.23M |
| Enterprise Value | 27.27M |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BioSenic has 251.31 million shares outstanding. The number of shares has decreased by -5.94% in one year.
| Shares Outstanding | 251.31M |
| Shares Change (YoY) | -5.94% |
| Shares Change (QoQ) | +30.85% |
| Owned by Insiders (%) | 9.37% |
| Owned by Institutions (%) | 4.19% |
| Float | 201.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.29 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.67 |
| EV / Sales | 9.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -11.55 |
Financial Position
The company has a current ratio of 0.40
| Current Ratio | 0.40 |
| Quick Ratio | 0.33 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -11.34 |
| Interest Coverage | -0.64 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -22.77% |
| Return on Capital (ROIC) | -32.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.29 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.26% in the last 52 weeks. The beta is 0.30, so BioSenic's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -94.26% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 21.42 |
| Average Volume (20 Days) | 1,839,957 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioSenic had revenue of EUR 2.87 million and -7.44 million in losses. Loss per share was -0.04.
| Revenue | 2.87M |
| Gross Profit | 2.87M |
| Operating Income | -3.61M |
| Pretax Income | -7.62M |
| Net Income | -7.44M |
| EBITDA | -3.36M |
| EBIT | -3.61M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 816,000 in cash and 26.79 million in debt, giving a net cash position of -25.98 million or -0.10 per share.
| Cash & Cash Equivalents | 816,000 |
| Total Debt | 26.79M |
| Net Cash | -25.98M |
| Net Cash Per Share | -0.10 |
| Equity (Book Value) | -20.40M |
| Book Value Per Share | -0.08 |
| Working Capital | -3.90M |
Cash Flow
In the last 12 months, operating cash flow was -2.37 million and capital expenditures 12,000, giving a free cash flow of -2.36 million.
| Operating Cash Flow | -2.37M |
| Capital Expenditures | 12,000 |
| Free Cash Flow | -2.36M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 100.00%, with operating and profit margins of -125.52% and -259.05%.
| Gross Margin | 100.00% |
| Operating Margin | -125.52% |
| Pretax Margin | -265.18% |
| Profit Margin | -259.05% |
| EBITDA Margin | -116.89% |
| EBIT Margin | -125.52% |
| FCF Margin | -82.24% |
Dividends & Yields
BioSenic does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 5.94% |
| Shareholder Yield | 5.94% |
| Earnings Yield | -879.41% |
| FCF Yield | -191.81% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioSenic has an Altman Z-Score of -6.48. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.48 |
| Piotroski F-Score | n/a |